PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 11:10 a.m. ET in Boston, MA. A live webcast of the presentation will be available on the News ...

Jacob Funds, a mutual fund company, released its fourth-quarter 2025 investor letter. A copy of the same can be downloaded here. After an optimistic quarter, equity markets corrected slightly in November. Although overall economic growth has been robust throughout the year, recent divergent data on consumer spending and the labor market have put doubt on future projections. This pattern has become somewhat familiar over the past few years, as conflicting economic data has become the norm. As for the Fund’s ...

Group 1: High Roller Technologies Inc - High Roller Technologies Inc (NYSE:ROLR) shares increased by 29.6% to $10.21 in pre-market trading following the closure of its registered direct offering [1] - The company sold 1.89 million common shares at a price of $13.21 per share, generating approximately $25 million in gross proceeds before fees [1] Group 2: Other Stocks in Pre-Market Trading - iOThree Ltd (NASDAQ:IOTR) saw a significant gain of 80.2% to $5.28 in pre-market trading after a 12% increase on Wednesday [5] - American Rebel Holdings Inc (NASDAQ:AREB) rose 53.1% to $0.67 following the announcement of a 1-for-20 reverse stock split effective February 2 [5] - IO Biotech Inc (NASDAQ:IOBT) increased by 24.3% to $0.26 after announcing plans to explore strategic alternatives, including a merger or asset sale [5] - Moderna Inc (NASDAQ:MRNA) gained 5.5% to $52.54 after releasing five-year median follow-up data from a Phase 2b trial involving an mRNA-based neoantigen therapy [5] Group 3: Stocks Declining in Pre-Market Trading - Galaxy Payroll Group Ltd (NASDAQ:GLXG) fell 21.5% to $1.93 after a 12% decline on Wednesday [5] - Boxlight Corp (NASDAQ:BOXL) decreased by 18.7% to $1.48 after a 46% increase on Wednesday [5] - Pineapple Financial Inc (NYSE:PAPL) dropped 17% to $1.17 after a 46% jump on Wednesday following the release of first-quarter financial results [5]

Core Insights - Biotech and healthcare sectors experienced notable movements in after-hours trading, particularly among small-cap companies, with several posting significant gains [1] Company Summaries - IO Biotech, Inc. (IOBT) saw a surge of 19.36% to $0.25 after announcing plans to explore various strategic alternatives to maximize stockholder value, including potential mergers, asset sales, or liquidation. The company is also considering further reductions in workforce and operational costs [2] - Cue Biopharma, Inc. (CUE) advanced 10.67% to $0.42, with gains attributed to speculative trading despite no specific news from the company [3] - InfuSystem Holdings, Inc. (INFU) climbed 7.19% to $9.24, continuing a trend of strength in the medical services sector without any new corporate updates [3] - Cabaletta Bio, Inc. (CABA) added 7.68% to $2.52, with investors likely reacting to the company's January 12 update on its 2026 strategic priorities, including plans for the development of rese-cel and advancements in automated manufacturing [4] - Iterum Therapeutics plc (ITRM) gained 3.60% to $0.3284, driven by modest buying interest despite the absence of fresh news [5] - BioCardia, Inc. (BCDA) rose 3.91% to $1.33, attracting buyers in after-hours trading without any new updates [5]

Core Insights - AtriCure (ATRC) is outperforming its peers in the Medical sector, with a year-to-date gain of 11.4% compared to the sector average of 0.7% [4] - The Zacks Rank for AtriCure is 2 (Buy), indicating strong analyst sentiment and an improving earnings outlook, with a 32.9% increase in the full-year earnings estimate over the past quarter [3] - AtriCure is part of the Medical - Products industry, which has seen a modest gain of 0.6% year-to-date, further highlighting AtriCure's strong performance within its specific industry [5] Industry Overview - The Medical sector consists of 951 individual stocks and currently holds a Zacks Sector Rank of 5, indicating its relative performance compared to other sectors [2] - The Medical - Biomedical and Genetics industry, to which Cabaletta Bio, Inc. (CABA) belongs, has a higher year-to-date gain of 10.9% and is ranked 95 among 469 stocks [6] - AtriCure's performance is notable as it exceeds both the overall Medical sector and its specific industry, showcasing its competitive position [4][5]